Exhibit 99.5
SELECTED FINANCIAL DATA
Reverse Stock Split
On December 29, 2022, we effected a 1-for-10 reverse stock split of our common stock. The total number of authorized shares of capital stock was amended from 260,000,000 to 110,000,000. The par value per common share remained unchanged. The audited consolidated financial statements of Gemini Therapeutics, Inc. included in the Annual Report on Form 10-K for the year ended December 31, 2021, and the unaudited condensed consolidated financial statements included in our Quarterly Reports on Form 10-Q for the periods ended March 31, 2022, June 30, 2022, and September 30, 2022, that are incorporated by reference into this prospectus are presented without giving effect to the reverse stock split. Except where the context otherwise requires, share numbers in this prospectus reflect the 1-for-10 reverse stock split of our common stock.
The following selected financial data has been derived from our audited consolidated financial statements included in our Annual Report on Form 10-K filed with the SEC on March 10, 2022, and our unaudited condensed consolidated financial statements included in our Quarterly Reports on Form 10-Q filed with the SEC on May 6, 2022, August 11, 2022, and November 10, 2022, as adjusted to reflect the reverse stock split for all periods presented. Our historical results are not indicative of the results that may be expected in the future and results of interim periods are not indicative of the results for the entire year. In addition, the below presented historical results do not present the pro forma impact of the reverse merger, as presented in the unaudited pro forma financial statements and accompanying notes for the nine months ended September 30, 2022, and the fiscal year ended December 31, 2021, contained in the Company’s Proxy Statement/Prospectus on Form S-4/A and incorporated herein by reference.
AS REPORTED (in thousands, except per share amounts):
Years Ended December 31, | ||||||||
2021 | 2020 | |||||||
Net loss and comprehensive loss | $ (71,869) | $ (40,837) | ||||||
Net loss per share, basic and diluted | $ (1.78) | $ (2.70) | ||||||
Weighted average common shares outstanding, basic and diluted | 40,362,303 | 15,115,129 | ||||||
Common shares outstanding at year end | 43,208,159 | 15,565,380 |
Three Months Ended March 31, | ||||||||
2022 | 2021 | |||||||
(Unaudited) | ||||||||
Net loss and comprehensive loss | $ (15,231) | $ (19,048) | ||||||
Net loss per share, basic and diluted | $ (0.35) | $ (0.59) | ||||||
Weighted average common shares outstanding, basic and diluted | 43,212,803 | 32,027,161 | ||||||
Common shares outstanding at period end | 43,227,159 | 43,002,144 |
Three Months Ended June 30, | ||||||||
2022 | 2021 | |||||||
(Unaudited) | ||||||||
Net loss and comprehensive loss | $ (7,090) | $ (16,447) | ||||||
Net loss per share, basic and diluted | $ (0.16) | $ (0.38) | ||||||
Weighted average common shares outstanding, basic and diluted | 43,230,523 | 43,041,856 | ||||||
Common shares outstanding at period end | 43,244,453 | 43,055,112 |
Six Months Ended June 30, | ||||||||
2022 | 2021 | |||||||
(Unaudited) | ||||||||
Net loss and comprehensive loss | $ (22,321) | $ (35,495) | ||||||
Net loss per share, basic and diluted | $ (0.52) | $ (0.94) | ||||||
Weighted average common shares outstanding, basic and diluted | 43,221,712 | 37,564,936 | ||||||
Common shares outstanding at period end | 43,244,453 | 43,055,112 |
Three Months Ended September 30, | ||||||||
2022 | 2021 | |||||||
(Unaudited) | ||||||||
Net loss and comprehensive loss | $ (3,277) | $ (18,551) | ||||||
Net loss per share, basic and diluted | $ (0.08) | $ (0.43) | ||||||
Weighted average common shares outstanding, basic and diluted | 43,264,616 | 43,091,822 | ||||||
Common shares outstanding at period end | 43,299,453 | 43,112,742 |
Nine Months Ended September 30, | ||||||||
2022 | 2021 | |||||||
(Unaudited) | ||||||||
Net loss and comprehensive loss | $ (25,598) | $ (54,046) | ||||||
Net loss per share, basic and diluted | $ (0.59) | $ (1.37) | ||||||
Weighted average common shares outstanding, basic and diluted | 43,236,171 | 39,427,476 | ||||||
Common shares outstanding at period end | 43,299,453 | 43,112,742 |
AS ADJUSTED FOR 1-FOR-10 REVERSE STOCK SPLIT (unaudited, in thousands, except per share amounts):
Years Ended December 31, | ||||||||
2021 | 2020 | |||||||
(Unaudited) | ||||||||
Net loss and comprehensive loss | $ (71,869) | $ (40,837) | ||||||
Net loss per share, basic and diluted | $ (17.81) | $ (27.02) | ||||||
Weighted average common shares outstanding, basic and diluted | 4,036,230 | 1,511,512 | ||||||
Common shares outstanding at year end | 4,320,815 | 1,556,538 |
Three Months Ended March 31, | ||||||||
2022 | 2021 | |||||||
(Unaudited) | ||||||||
Net loss and comprehensive loss | $ (15,231) | $ (19,048) | ||||||
Net loss per share, basic and diluted | $ (3.52) | $ (5.95) | ||||||
Weighted average common shares outstanding, basic and diluted | 4,321,280 | 3,202,716 | ||||||
Common shares outstanding at period end | 4,322,715 | 4,300,214 |
Three Months Ended June 30, | ||||||||
2022 | 2021 | |||||||
(Unaudited) | ||||||||
Net loss and comprehensive loss | $ (7,090) | $ (16,447) | ||||||
Net loss per share, basic and diluted | $ (1.64) | $ (3.82) | ||||||
Weighted average common shares outstanding, basic and diluted | 4,323,052 | 4,304,185 | ||||||
Common shares outstanding at period end | 4,324,445 | 4,305,511 |
Six Months Ended June 30, | ||||||||
2022 | 2021 | |||||||
(Unaudited) | ||||||||
Net loss and comprehensive loss | $ (22,321) | $ (35,495) | ||||||
Net loss per share, basic and diluted | $ (5.16) | $ (9.45) | ||||||
Weighted average common shares outstanding, basic and diluted | 4,322,171 | 3,756,493 | ||||||
Common shares outstanding at period end | 4,324,445 | 4,305,511 |
Three Months Ended September 30, | ||||||||
2022 | 2021 | |||||||
(Unaudited) | ||||||||
Net loss and comprehensive loss | $ (3,277) | $ (18,551) | ||||||
Net loss per share, basic and diluted | $ (0.76) | $ (4.30) | ||||||
Weighted average common shares outstanding, basic and diluted | 4,326,461 | 4,309,182 | ||||||
Common shares outstanding at period end | 4,329,945 | 4,311,274 |
Nine Months Ended September 30, | ||||||||
2022 | 2021 | |||||||
(Unaudited) | ||||||||
Net loss and comprehensive loss | $ (25,598) | $ (54,046) | ||||||
Net loss per share, basic and diluted | $ (5.92) | $ (13.71) | ||||||
Weighted average common shares outstanding, basic and diluted | 4,323,617 | 3,942,747 | ||||||
Common shares outstanding at period end | 4,329,945 | 4,311,274 |